Continuous glucose monitoring technology clusters around three interlinked technical domains: (1) enzymatic electrochemical transduction using glucose oxidase (GOx) on implantable working electrodes, (2) electrochemical impedance spectroscopy (EIS) as an in-line diagnostic and calibration tool, and (3) computational intelligence layers including machine learning (ML), Kalman filtering, and sensor fusion algorithms.

No filed patents in this dataset claim a commercialized non-enzymatic detection approach for subcutaneous CGM. The dominant paradigm remains GOx-based amperometric sensing with hydrogen peroxide (H₂O₂) as the redox intermediate, or oxygen-differential sensing as a quasi-orthogonal redundant modality. According to WHO estimates, over 500 million people live with diabetes globally, making accurate CGM a critical public health technology.

Sensor architecture has evolved from single working electrodes requiring frequent finger-stick calibrations toward multi-electrode redundant systems with factory calibration, EIS-based health monitoring, and AI-corrected glucose value outputs. The interstitial fluid (ISF) glucose lag relative to blood glucose remains a recognized physiological challenge, addressed through Kalman filtering, state-transition modeling, and short-term predictive algorithms. Regulatory bodies including the FDA have established iCGM classification pathways that reward redundant electrode architectures with built-in failure detection.

This landscape is derived from patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full industry. Explore the full patent database via PatSnap Analytics.

The dominant application across the dataset is type 1 and type 2 diabetes management, including closed-loop artificial pancreas systems. CGM sensor output feeds insulin delivery controllers via basal rate adaptation algorithms and risk-metric frameworks. Roche Diabetes Care GmbH describes interval-control algorithms that determine basal insulin rate adjustments based on CGM-derived risk metrics and rate-of-change (2021, ES). Medtronic's safeguarding framework uses CGM data to trigger insulin-on-board (IOB) compensation and generate alerts when sensor glucose deviates from predictions (2015, KR).

Customers across the life sciences sector are using PatSnap Eureka to map CGM application domains, including digital health platforms. Dexcom and Welldoc have filed multiple patents covering CGM data analytics platforms that generate personalized health recommendations, engagement interventions, and multi-state user management at population scale. Welldoc's 2026 JP filing and Dexcom's 2025 JP filing represent the leading edge of population-scale glucose analytics. According to the NIH, digital diabetes management tools have demonstrated significant HbA1c reduction in clinical settings.

One retrieved patent from Janssen Biotech describes Raman spectroscopy combined with chemometric modeling for in-line glucose monitoring in bioreactors producing glycosylated molecules (2024, CN). This optical, non-invasive approach — distinct from implantable enzymatic sensors — represents a non-enzymatic glucose detection pathway adapted for industrial bioprocessing rather than clinical subcutaneous CGM.

Scalp-worn EEG-based glucose state inference (SyncNeuro, 2025, JP) and Kalman filter-based blood glucose estimation from tissue sensor measurements (EyeSense GmbH, 2024, JP) reflect optical and non-enzymatic signals being explored at the research frontier. Explore materials and chemistry innovation relevant to CGM enzyme membrane design on PatSnap.